Skip to Main Content

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is filling up quickly as we expect a visitor from ancient times, promenade extensively with the official mascot, and plan to escort Mrs. Pharmalot to a musical outing. Speaking of which, the rotation for our listening party will include this, this, this and this. And what about you? Once again, this is a fine time to enjoy the great outdoors — lakes, beaches and woods are beckoning (but watch out for ticks). This may be an opportunity to catch up on your reading or do some binge watching in front of the telly. Or you could reach out to someone special. Well, whatever you do, have a grand time. But be safe — be careful when knocking on doors. Enjoy, and see you soon …

Eli Lilly expects Medicare to back down from strict coverage limits on new Alzheimer’s drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients, Reuters tells us. Lilly plans to release results from a trial of its experimental drug before the end of June. More data on Leqembi, a drug from Eisai and Biogen, is also expected in coming months. Currently, Medicare will only pay for anti-amyloid drugs approved under the less rigorous accelerated review if patients are enrolled in a clinical trial. Leqembi received accelerated approval from the Food and Drug Administration earlier this year, and a decision on full approval is due by July.


A pair of key senators significantly changed a proposal to cap insulin costs, STAT reports. The new legislation would cap insured patient insulin costs at $35 per month for at least one insulin of each type and dosage form, and require pharmacy benefit managers to pass through rebates they collect from insulin manufacturers to the insurance plans that employ them. The bill would create a new, expedited pathway for the FDA to consider biosimilars that would be alternatives to biologics without adequate competition and would allow Medicare drug plans to put biosimilars on their formularies as soon as they come on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.